Compare SHEN & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | CMPS |
|---|---|---|
| Founded | 1902 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.5M | 598.7M |
| IPO Year | N/A | 2020 |
| Metric | SHEN | CMPS |
|---|---|---|
| Price | $10.87 | $5.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $26.00 | $16.43 |
| AVG Volume (30 Days) | 300.6K | ★ 1.5M |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $351,674,000.00 | N/A |
| Revenue This Year | $10.77 | N/A |
| Revenue Next Year | $6.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.24 | N/A |
| 52 Week Low | $9.67 | $2.25 |
| 52 Week High | $15.84 | $7.09 |
| Indicator | SHEN | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 52.24 |
| Support Level | $10.65 | $4.90 |
| Resistance Level | $10.96 | $5.57 |
| Average True Range (ATR) | 0.34 | 0.35 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 74.92 | 96.67 |
Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.